industry sponsored symposia - era-edta2016.org336 held jointly with industry sponsored symposia...
TRANSCRIPT
335
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
INDUSTRY SPONSORED SYMPOSIA
pageSunday, May 22, 2016 13:30-15:00Hall D Fresenius Medical Care 336Hall E Vifor Fresenius Medical Care Renal Pharma 337Hall B B.Braun 338Hall C Baxter Healthcare 339Hall G Alexion Pharma International 340Hall K Chiesi Farmaceutici 341Lounge 3 Shire International 342Hall N Immunodiagnostic Systems & Natto Pharma 343
18:45-19:45Hall G Merck Sharp & Dohme 344Hall K Amgen 345Hall N Bayer 346
Monday, May 23, 2016 13:30-15:00Hall D Baxter Healthcare 347Hall E Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance 348Hall F Otsuka Pharmaceutical Europe 349Hall B Vifor Fresenius Medical Care Renal Pharma 350Hall C Astra Zeneca 351Hall G Sanofi Genzyme 352Hall K Novartis Pharma 353Hall M NxStage Medical 354Hall N Raptor Pharmaceuticals 355
Tuesday, May 24, 2016 12:15-13:15Hall K Sigma-Tau 356
336
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Sunday, May 22, 2016 13:30-15:00Hall D
Improving Outcomes of Advanced Chronic Kidney Disease Patients by "Personalized and Precise Renal Replacement Therapy"
Chairs: Andrew Davenport, London, United Kingdom Mariano J. Rodríguez Portillo, Cordoba, Spain
Cardiovascular Protection: How to balance benefit/risk by fluid and electrolytes managementDaniel Schneditz, Graz, Austria
Improving Intradialytic Stability: How to reduce the risk of extracorporeal thrombotic eventsMartin Kuhlmann, Berlin, Germany
Uremic Toxicity, Gut-Kidney Axis and Renal Replacement Therapy: How to improve outco-me of advanced CKD patients by a multi-targeted approachGriet Glorieux, Ghent, Belgium
Organised by FRESENIUS MEDICAL CARE
337
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Sunday, May 22, 2016 13:30-15:00Hall E
Protecting heart, vessels and bone - new ways to control phosphorus and potassium
Chairs: Markus Ketteler, Coburg, Germany Alexander Rosenkranz, Graz, Austria
Hyperphosphatemia - understanding the challengesLaurent Juillard, Lyon, France
Advances in the management of hyperphosphatemiaPhilip Kalra, Manchester, United Kingdom
A new approach in potassium management - can we change the treatment paradigm?Matthew R. Weir, Baltimore, U.S.A.
Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
338
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Sunday, May 22, 2016 13:30-15:00Hall B
Optimal Treatment Targets in Renal Replacement Therapy - How to achieve them?
Chair: Joachim Hoyer, Marburg, Germany
Tailor-made hemodialysate composition - effects on hemodynamic stabilityFrancesco Locatelli, Lecco, Italy
Convection volume in HDF - lessons learned for daily practicePeter J. Blankestijn, Utrecht, The Netherlands
Renal dose achievement in AKI - influential factorsAntoine Schneider, Lausanne, Switzerland
Organised by B.BRAUN
339
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Sunday, May 22, 2016 13:30-15:00Hall C
Uremic toxins: urea, β2-microglobulin and beyond
Chair: Peter Stenvinkel, Stockholm, Sweden
From low-flux HD to high-flux and HDF: what's next? Muriel Grooteman, Amsterdam, The Netherlands
Uremic toxins beyond β2m: what role do they play?Colin Hutchison, Hawke's Bay, New Zealand
Albumin removal by dialysis: is there reason to be concerned?Peter Stenvinkel, Stockholm, Sweden
Organised by BAXTER HEALTHCARE
340
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Sunday, May 22, 2016 13:30-15:00Hall G
TMA: multiple causes for a disease with 100 faces?
Chair: Manuel Praga, Madrid, Spain
Recognising the many faces of TMAManuel Praga, Madrid, Spain
Facing the future: rapid differential diagnosis of TMAChristian Haas, Lübeck, Germany
The changing face of TMA diagnosis for the kidney transplant patientJulien Zuber, Paris, France
Organised by ALEXION PHARMA INTERNATIONAL
341
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Sunday, May 22, 2016 13:30-15:00Hall K
Advancements in immunosuppression: are all tacrolimus formulations the same?
Chair: Rainer Oberbauer, Vienna, Austria
Control and optimization: the answer in PKPierre Marquet, Limoges, France
Management and clinical outcomes: the answer of the clinicianJulio Pascual, Barcelona, Spain
Organised by CHIESI FARMACEUTICI
342
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Sunday, May 22, 2016 13:30-15:00Lounge 3
Rare diseases and the kidney: unexplained story and complexity of Fabry disease
Chairs: Gere Sunder-Plassmann, Vienna, Austria Olivier Devuyst, Zurich, Switzerland
Welcome and IntroductionGere Sunder-Plassmann, Vienna, Austria
Overview and Common Misdiagnosis of Rare Diseases in NephrologyOlivier Devuyst, Zurich, Switzerland
Pathophysiology and Treatment of Fabry Disease: It’s Not as Simple as we May ThinkSandro Feriozzi, Viterbo, Italy
How to Identify Fabry Disease Among Renal Patients: The Importance of ScreeningPablo Neumann, Buenos Aires, Argentina
Organised by SHIRE INTERNATIONAL
343
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Sunday, May 22, 2016 13:30-15:00Hall N
The infernal triad: matrix-gla-protein, vitamin K and vascular calcification
Chairs: Jürgen Floege, Aachen, Germany Etienne Cavalier, Liege, Belgium
Vascular calcification in CKD patientsZiad Massy, Paris, France
Vitamin K-dependent matrix Gla-protein: a crucial switch to control ectopic mineralizationLeon Schurgers, Maastricht, The Netherlands
Vitamin K2: an essential nutrient for cardiovascular healthKatarzyna Maresz, Krakow, Poland
Organised by IMMUNODIAGNOSTIC SYSTEMS & NATTO PHARMA
344
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Sunday, May 22, 2016 18:45-19:45Hall G
Treatment of Hepatitis C in Patients with Chronic Kidney Disease: Challenges and Opportunities
Chair: Marcus Säemann, Vienna, Austria
The Burden of Hepatitis C in Patients with Chronic Kidney DiseaseAnnette Bruchfeld, Stockholm, Sweden
Therapeutic Options and Guidelines for the Treatment of Hepatitis C in Patients with Chronic Kidney DiseaseDavid Roth, Miami, U.S.A.
Organised by MERCK SHARP & DOHME
345
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Sunday, May 22, 2016 18:45-19:45Hall K
Treating secondary hyperparathyroidism with calcimimetics; new insights
Chair: David Wheeler, London, United Kingdom
Lessons learnt from the EVOLVE studyJürgen Floege, Aachen, Germany
Etelcalcetide - a new injectable calcimimetic for the treatment of secondary hyperparathyroidismMarkus Ketteler, Coburg, Germany
Organised by AMGEN
346
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Sunday, May 22, 2016 18:45-19:45Hall N
DKD: getting to the heart of the matter
Chair: Hermann Haller, Hannover, Germany
Cardiovascular outcomes in patients with diabetic kidney disease: epidemiology and patho-physiologyPatrick Rossignol, Nancy, France
Emerging therapies for reducing renal and cardiovascular risk in patients with diabetic kidney diseasePeter Rossing, Gentofte, Denmark
Organised by BAYER
347
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Monday, May 23, 2016 13:30-15:00Hall D
Optimizing the ESRD patient journey and RRT clinical-economic outcomes
Chair: Simon Davies, Stoke-on-Trent, United Kingdom
Challenging the deadly paradigm of RRT modality transitions: an integrated approach to the patient ESRD journey Wim Van Biesen, Ghent, Belgium
Doing the right thing at the right time: shared decision-making with RRT modality selection Eero Honkanen, Helsinki, Finland
The role of RPM and telemedicine in optimizing RRT modality outcomes and facilitating healthy transitions Claus Peter Schmitt, Heidelberg, Germany
Organised by BAXTER HEALTHCARE
348
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Monday, May 23, 2016 13:30-15:00Hall E
SGLT2 inhibition: Is this a novel approach to prevent the progression of diabetic kidney disease?
Chair: Gert Mayer, Innsbruck, Austria
Current challenges when treating patients with Type 2 Diabetes & Kidney DiseaseVlado Perkovic, Sydney, Australia
New evidence at the interface of Type 2 Diabetes & Kidney Disease: The EMPA-REG OUTCOME® TrialChristoph Wanner, Würzburg, Germany
SGLT2 inhibition: How does it work in the kidney?David Cherney, Toronto, Canada
Implications for clinical practiceVlado Perkovic, Sydney, Australia
Organised by BOEHRINGER INGELHEIM & ELI LILLY AND COMPANY DIABETES ALLIANCE
349
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Monday, May 23, 2016 13:30-15:00Hall F
ADPKD Treatment Update
Chair: Roser Torra, Barcelona, Spain
Welcome and introductionRoser Torra, Barcelona, Spain
Updated results of TEMPO 3:4Vicente Torres, Rochester, U.S.A.
How to identify patients with rapidly progressing ADPKDHenrik Birn, Aarhus, Denmark
Initiation and maintenance of tolvaptan: From theory into practice and early insight from the clinicRoman-Ulrich Müller, Cologne, Germany
Panel discussionRoser Torra, Barcelona, Spain
Closing remarksRoser Torra, Barcelona, Spain
Organised by OTSUKA PHARMACEUTICAL EUROPE
350
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Monday, May 23, 2016 13:30-15:00Hall B
New insights into iron metabolism and deficiency
Chairs: Angel Luis Martin de Francisco, Santander, Spain Kai-Uwe Eckardt, Erlangen, Germany
ID prevalence in patients with CKD - a matter of definition?Kai-Uwe Eckardt, Erlangen, Germany
Iron pathophysiology - its complexity and our knowledge gapsTomas Ganz, Los Angeles, U.S.A.
Diagnosing and treating ID/IDA - meeting your patient's needsJolanta Malyszko, Bialystok, Poland
Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
351
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Monday, May 23, 2016 13:30-15:00Hall C
Management of Hyperkalemia: Challenges and Considerations in Patients with CKD
Chair: David Goldsmith, London, United Kingdom
Pathophysiology and Risk of HyperkalemiaJohannes F.E. Mann, Munich, Germany
Current and Emerging Options for Outpatient Treatment of HyperkalemiaMartin H. de Borst, Groningen, The Netherlands
Supported by an educational grant from ASTRA ZENECA
352
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Monday, May 23, 2016 13:30-15:00Hall G
Unknown unknowns in Chronic Kidney Disease
Chair: Alberto Ortiz, Madrid, Spain
What is an unknown unknown in Chronic Kidney Disease? Prevalence of undiagnosed primary and secondary causes of CKDGiuseppe Castellano, Bari, Italy
Utility of renal biopsies in diagnosis and treatment of secondary and rare causes of CKDAlberto Ortiz, Madrid, Spain
KDIGO Conference on Fabry Nephropathy: Management of rare causes of Chronic Kidney DiseaseBojan Vujkovac, Slovenj Gradec, Slovenia
Organised by SANOFI GENZYME
353
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Monday, May 23, 2016 13:30-15:00Hall K
Working to Preserve Renal Function in Patients with Tuberous Sclerosis Complex
Chair: J. Chris Kingswood, Brighton, United Kingdom
Natural course of renal function in patients with TSC Bernard Zonnenberg, Utrecht, The Netherlands
Current monitoring guidelines and treatment options for TSC-related renal manifestationsKlemens Budde, Berlin, Germany
Safety and efficacy of mTOR inhibitors J. Chris Kingswood, Brighton, United Kingdom
Organised by NOVARTIS PHARMA
354
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Monday, May 23, 2016 13:30-15:00Hall M
Challenges to improve hemodialysis outcomes: are "frequent" and "home" the answers?
Chairs: Eric Goffin, Bruxelles, Belgium Maxence Ficheux, Caen, France
Home HD: How it looks and how it worksShashidhar Cherukuri, Wolverhampton, United Kingdom
The ‘suitable’ patient and prescribing home HDNatalie Borman, Portsmouth, United Kingdom
The European experience: Clinical outcome from the KIHDNEy cohortPer Westerlund, Kristianstad, Sweden
Patient experience: what are the success factorsHafedh Fessi, Paris, France
Organised by NXSTAGE MEDICAL
355
Indus
try s
pons
ored
symp
osIa
F i n a l P r o g r a m m e
Industry Sponsored Symposia
Monday, May 23, 2016 13:30-15:00Hall N
Rare Renal Diseases Are Growing Up
Chair: Rainer Oberbauer, Vienna, Austria
Cystinosis vs CKD: Growth and neurocognitive development in childhoodDieter Haffner, Hannover, Germany
Managing the Adolescent PatientGraham Lipkin, Birmingham, United KingdomLarissa Kerecuk, Birmingham, United Kingdom
Cystinosis in Adults; An Emerging PopulationAlbane Brodin-Sartorius, Paris, France
Organised by RAPTOR PHARMACEUTICALS
356
Held jointly with
w w w . e r a - e d t a 2 0 1 6 . o r g
Industry Sponsored SymposiaInd
ustr
y spo
nsor
ed sy
mpos
Ia
Tuesday, May 24, 2016 12:15-13:15Hall K
Secondary Carnitine Deficiency in Dialysis Patients-Shall We Supplement it?
Chairs: Ronald Wanders, Amsterdam, The Netherlands Tim Ulinski, Paris, France
Carnitine in Human Health and Disease Including Genetic Metabolic DisordersRonald J.A.Wanders, Amsterdam, The Netherlands
Characteristics of Dialysis-Related Carnitine Deficiency - Effectiveness of L-carnitine for the Treatment of Erythropoietin-Resistant Renal AnaemiaStephanie Reuter Lange, Adelaide, Australia
Carnitine Levels, Myocardial Function and Survival Outcomes in Children Receiving Chronic Hemodialysis and Continuous Renal Replacement TherapyAsha Moudgil, Washington, U.S.A.
Organised by SIGMA-TAU